Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
作者信息
Kato Shumei, Subbiah Vivek, Kurzrock Razelle
出版信息
J Natl Compr Canc Netw. 2017 Jul;15(7):863-866. doi: 10.6004/jnccn.2017.0127.
Abstract
摘要
相似文献
1
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
J Natl Compr Canc Netw. 2017 Jul;15(7):863-866. doi: 10.6004/jnccn.2017.0127.
2
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
J Natl Compr Canc Netw. 2018 Oct;16(10):1259-1268. doi: 10.6004/jnccn.2018.7046.
3
Targeting the human kinome for cancer therapy.
Crit Rev Oncog. 2012;17(1):vi-vii. doi: 10.1615/critrevoncog.v17.i1.10.
4
The pathway to clinical use of a cancer biomarker.
Scand J Clin Lab Invest Suppl. 2016;245:S17-21. doi: 10.1080/00365513.2016.1206441. Epub 2016 Jul 13.
5
Clinical applications of PD-L1 bioassays for cancer immunotherapy.
J Hematol Oncol. 2017 May 17;10(1):110. doi: 10.1186/s13045-017-0479-y.
6
Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?
J Natl Compr Canc Netw. 2017 Jul;15(7):859-862. doi: 10.6004/jnccn/2017.0126.
7
Biomarkers for immunotherapy in urological cancers.
Curr Opin Urol. 2018 Jan;28(1):25-28. doi: 10.1097/MOU.0000000000000465.
8
The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
J Clin Oncol. 2009 Dec 10;27(35):5866-7. doi: 10.1200/JCO.2009.24.8013. Epub 2009 Nov 2.
9
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Methods Mol Biol. 2018;1765:281-297. doi: 10.1007/978-1-4939-7765-9_18.
10
[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26.
引用本文的文献
1
Gut microbiota shapes cancer immunotherapy responses.
NPJ Biofilms Microbiomes. 2025 Jul 25;11(1):143. doi: 10.1038/s41522-025-00786-8.
2
Precision Medicine: Disease Subtyping and Tailored Treatment.
Cancers (Basel). 2023 Jul 28;15(15):3837. doi: 10.3390/cancers15153837.
3
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies.
NPJ Precis Oncol. 2022 Mar 28;6(1):18. doi: 10.1038/s41698-022-00259-7.
4
Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.
Int J Mol Sci. 2021 May 12;22(10):5111. doi: 10.3390/ijms22105111.
5
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.
Ther Adv Med Oncol. 2021 Feb 27;13:1758835920987658. doi: 10.1177/1758835920987658. eCollection 2021.
6
Transcriptomics and solid tumors: The next frontier in precision cancer medicine.
Semin Cancer Biol. 2022 Sep;84:50-59. doi: 10.1016/j.semcancer.2020.09.007. Epub 2020 Sep 17.
7
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
J Transl Med. 2020 Feb 3;18(1):49. doi: 10.1186/s12967-020-02231-0.
8
Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
Expert Rev Hematol. 2019 Nov;12(11):959-973. doi: 10.1080/17474086.2019.1660159. Epub 2019 Sep 12.
9
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.
10
Analysis of Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00183. Epub 2018 Nov 15.
本文引用的文献
1
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
JAMA Oncol. 2016 Nov 1;2(11):1452-1459. doi: 10.1001/jamaoncol.2016.2129.
2
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Cancer Res. 2016 Jul 1;76(13):3690-701. doi: 10.1158/0008-5472.CAN-15-3043. Epub 2016 May 18.
3
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis.
JAMA Oncol. 2016 Jun 1;2(6):719-20. doi: 10.1001/jamaoncol.2016.0078.
4
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
J Natl Cancer Inst. 2015 Sep 15;107(11). doi: 10.1093/jnci/djv253. Print 2015 Nov.
5
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
6
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
J Clin Oncol. 2015 Nov 10;33(32):3817-25. doi: 10.1200/JCO.2015.61.5997. Epub 2015 Aug 24.
7
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
8
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
9
Omics and therapy - a basis for precision medicine.
Mol Oncol. 2012 Apr;6(2):128-39. doi: 10.1016/j.molonc.2012.02.009. Epub 2012 Mar 8.
Zotero 插件